Welcome to European Tribune. It's gone a bit quiet around here these days, but it's still going.
If the clinical trials referenced are phase I or II, then it will take until the middle of this decade. But Sven's comments lead me to believe that they're stage III trials. If so, and assuming the trials demonstrate efficacy and no unexpected complications show up relative to the phase II trial, it should be possible to get it approved for the sort of patients the trial(s) have demonstrated efficacy in before this time next year.

Normally, there will be subsequent clinical trials that seek to expand the drug to more marginal patient groups/disorders. Clinical trials usually start with the most promising uses, on the theory that if you don't get a signal from your most promising trial then you probably won't get a signal at all (and commercially it's better to start with a strong effect and then move to more marginal groups than the other way around).

- Jake

Friends come and go. Enemies accumulate.

by JakeS (JangoSierra 'at' gmail 'dot' com) on Fri Dec 31st, 2010 at 12:17:03 PM EST
[ Parent ]

Others have rated this comment as follows:


Occasional Series